$404 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 38 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ITCI | New | INTRA CELLULAR THERAPIES INC | $20,143,000 | – | 587,089 | +100.0% | 4.99% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $15,235,000 | – | 1,322,500 | +100.0% | 3.77% | – |
| AVDL | New | AVADEL PHARMACEUTICALS PLCsponsored adr | $12,269,000 | – | 1,625,000 | +100.0% | 3.04% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS | $9,746,000 | – | 2,825,000 | +100.0% | 2.41% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $9,304,000 | – | 197,500 | +100.0% | 2.30% | – |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $8,537,000 | – | 387,500 | +100.0% | 2.11% | – |
| ISEE | New | IVERIC BIO INC | $7,808,000 | – | 910,000 | +100.0% | 1.93% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $5,741,000 | – | 187,500 | +100.0% | 1.42% | – |
| SELB | New | SELECTA BIOSCIENCES INC | $5,345,000 | – | 2,364,204 | +100.0% | 1.32% | – |
| NLTX | New | NEOLEUKIN THERAPEUTICS INC | $4,589,000 | – | 372,500 | +100.0% | 1.14% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $4,219,000 | – | 56,000 | +100.0% | 1.04% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INCcall | $3,431,000 | – | 100,000 | +100.0% | 0.85% | – |
| IMMU | New | IMMUNOMEDICS INC | $3,174,000 | – | 150,000 | +100.0% | 0.79% | – |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $3,130,000 | – | 22,500 | +100.0% | 0.78% | – |
| MDCO | New | MEDICINES CO | $1,843,000 | – | 21,700 | +100.0% | 0.46% | – |
| QURE | New | UNIQURE NV | $1,792,000 | – | 25,000 | +100.0% | 0.44% | – |
| ACST | New | ACASTI PHARMA INCcl a new | $1,519,000 | – | 620,000 | +100.0% | 0.38% | – |
| CCXI | New | CHEMOCENTRYX INC | $1,384,000 | – | 35,000 | +100.0% | 0.34% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INCcall | $1,152,000 | – | 100,000 | +100.0% | 0.28% | – |
| ZFGN | New | ZAFGEN INC | $1,110,000 | – | 1,000,000 | +100.0% | 0.28% | – |
| XFOR | New | X4 PHARMACEUTICALS INC | $428,000 | – | 40,000 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.